Early catheter ablation vs. antiarrhythmic drugs in treatment-naïve ischaemic ventricular tachyarrhythmias: a meta-analysis of randomized controlled trials.

Abstract

Antiarrhythmic drugs (AADs) have traditionally been used as first-line therapy for ventricular tachycardia (VT) but are frequently associated with systemic toxicities and drug interactions. Therefore, we performed a meta-analysis comparing early catheter ablation (CA) with AAD therapy as initial treatment for VT in patients with prior myocardial infarction. PubMed, Embase, and the Cochrane Library were searched for randomized controlled trials comparing CA vs. AAD in patients naïve to both strategies. Meta-analysis was performed using Review Manager. Three randomized trials including 618 patients were analysed. No significant differences were observed in all-cause mortality, appropriate implantable cardioverter-defibrillator (ICD) therapies (including shocks and antitachycardia pacing), ventricular arrhythmia storm, hospitalizations, or adverse events between strategies. Leave-one-out sensitivity analysis identified one trial as the primary contributor to between-study heterogeneity. Early catheter ablation provides similar efficacy to first-line antiarrhythmic drug therapy for major arrhythmic and survival outcomes, with reductions in hospitalizations and treatment-related adverse events, although largely driven by one trial. These findings support consideration of CA as a first-line therapeutic strategy in selected patients with ischaemic VT.